03T0330

Deactivation of Psychoactive Drugs Using an Activated Carbon Based Drug Disposal System

Behnam Dasht Bozorg¹, Yujin Kim¹, Yang Song¹, Mahima Manian¹, William Fowler², Andrew Korey², Ajay K. Banga¹

¹ Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA 30341

² Verde Technologies, 12701 Whitewater Drive, Minnetonka, MN 55343

ANNUAL MEETING AND EXPOSITION

NOVEMBER 13–17, 2016

COLORADO CONVENTION CENTER, DENVER



PURPOSE

Proper disposal of expired, unwanted, or unused medications in households will help reduce harm from accidental exposure or intentional misuse. For a safe and secure disposal, FDA suggests that consumers transfer their unneeded medicines to take-back programs or to DEAauthorized collectors. As an alternative, FDA recommends mixing medicines with an unpalatable substance such as dirt or used coffee grounds and then discarding it in household trash. Other than the risk of these medications to be found and used by others, they can end up contaminating food and water supplies. Therefore, a safe and secure drug disposal system seems to be beneficial for household use. An activated carbon based drug deactivation system offers safe disposal of unused medications. Activated carbon is considered to be a universal adsorbent and exerts strong physical adsorption forces due to its highly porous structure. It is a convenient and easy system in that consumers can simply dispose their unwanted medications by putting them in a pouch containing activated carbon, adding water and closing the bag. The purpose of this study was to evaluate this drug deactivation system for its efficiency in deactivating a number of psychoactive medications.

METHODS

Medications included in this study were lorazepam 20 mg tablet, alprazolam 2 mg tablet, temazepam 30 mg capsule, and dextroamphetamine sulfate 10 mg tablet.

Deactivation Study: Ten tablets/capsules of each drug were placed in a separate re-sealable plastic pouch $(15cm \times 10cm)$, which contains 15 grams of granulated activated carbon enclosed by a thin layer of a water-soluble polymer. Warm $(\sim 43^{\circ}\text{C})$ tap water (50mL) was added, and pouches were shaken, sealed, and then stored undisturbed at room temperature. Drug deactivation was evaluated at different time points: 8h, 1, 2, 4, 7, 14, 21, and 28 days. Samples taken from the pouches were centrifuged, filtered, and then further analyzed by HPLC-UV.

Desorption Study: After 28 days, contents of each pouch were transferred into a bottle, and 200mL of deionized water was added. The bottles were shaken for 1 hour (30 cycles per min) and then stored at room temperature for 23 hours. Following the water washout study, the water content was replaced with 30% ethanol, and the same procedure was repeated. Samples were taken from the water and ethanol washouts and then later analyzed to investigate the amount of drug leached out of the activated carbon.




Figure 1. A schematic diagram of deactivation study

RESULTS

Results of the deactivation study showed that on average, more than 92% of drugs were deactivated by 8 hours. All drugs reached close to 100% deactivation by the end of 28 day period (Fig 2).

Desorption study demonstrated that for lorazepam, alprazolam, temazepam, and dextroamphetamine, 0.21%, 0.00%, 0.05%, and 0.00% of drug was leached into the water, respectively. For ethanol washouts, the percentage of drug leached was as following, respectively: 0.25%, 0.00%, 0.04%, and 9.39%.




Figure 2. Deactivation profile of all medications during a 28 day period

CONCLUSION

Activated carbon was successfully able to deactivate the psychoactive medications tested. The deactivation was rapid, and the amount of drug that was leached by water and ethanol for most medications, was insignificant suggesting activated carbon based drug deactivation system provides a convenient, secure, and effective disposal method for unused medication that can be used in households.

REFERENCES

U.S. Food and Drug Administration. (2015, June 4). Retrieved July 14, 2016, from

http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm 101653.htm

FUNDING / GRANTS

This project has been funded in whole or in part with Federal funds form the National Institute on Drug Abuse, NIH, Dept. of Health and Human Services, under Contract No. HHSN271201400068C.